Effect of Tarragon on type 2 diabetes

Studying supplementation of Tarragon on glycemic condition, lipid profile, antioxidant activity and insulin intolerance in diabetes type 2 patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170822035834N3

Enrollment

Registered

2018-03-05

Start date

2017-09-23

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. Type 2 diabetes mellitus

Interventions

Intervention 1: Control group: 30 subjects, capsule containing 500 mg placebo, three times a day, after each meal. Intervention 2: Intervention group: 30 people, capsule containing 500 mg of powdered

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Moderate physical activity Fasting blood glucose between 140 to 200 cooperation tendency

Exclusion criteria

Exclusion criteria: Insulin use HbA1c more than 9% or less than 6% Pregnancy and breast feeding

Design outcomes

Primary

Measure	Time frame
Blood sugar: type 2 diabetic people with FBS in range of 140-200 mg/dl. Timepoint: At the beginning and the end of study. Method of measurement: ELISA kit.;HbA1c: type 2 diabetic people with HbA1c 7-9%. Timepoint: beginning and end of study. Method of measurement: ELISA kit.;Insulin: rate of insulin secretion in patients. Timepoint: At the beginning and the end of study. Method of measurement: ELISA kit.;High Density Lipoprotein (HDL). Timepoint: At the beginning and the end of study. Method of measurement: ELISA kit.;Low Density Lipoprotein (LDL). Timepoint: At the beginning and the end of study. Method of measurement: ELISA kit.;Very Low Density Lipoprotein (VLDL). Timepoint: At the beginning and the end of study. Method of measurement: ELISA kit.;. Timepoint: . Method of measurement: .;Blood Cholestrol. Timepoint: At the beginning and the end of study. Method of measurement: ELISA kit.;Blood Triglyceride. Timepoint: At the beginning and the end of study. Method of measurement: ELISA kit.	—

Measure

Time frame

Blood sugar: type 2 diabetic people with FBS in range of 140-200 mg/dl. Timepoint: At the beginning and the end of study. Method of measurement: ELISA kit.;HbA1c: type 2 diabetic people with HbA1c 7-9%. Timepoint: beginning and end of study. Method of measurement: ELISA kit.;Insulin: rate of insulin secretion in patients. Timepoint: At the beginning and the end of study. Method of measurement: ELISA kit.;High Density Lipoprotein (HDL). Timepoint: At the beginning and the end of study. Method of measurement: ELISA kit.;Low Density Lipoprotein (LDL). Timepoint: At the beginning and the end of study. Method of measurement: ELISA kit.;Very Low Density Lipoprotein (VLDL). Timepoint: At the beginning and the end of study. Method of measurement: ELISA kit.;. Timepoint: . Method of measurement: .;Blood Cholestrol. Timepoint: At the beginning and the end of study. Method of measurement: ELISA kit.;Blood Triglyceride. Timepoint: At the beginning and the end of study. Method of measurement: ELISA kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Gholamreza Houshmand

Mazandaran University of Medical Scienses

g.houshmand@mazums.ac.ir+98 11 3354 3081

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026